Evaluation of therapy for lymphoma

Seminars in Nuclear Medicine

Volumn 35, Issue 3 SPEC. ISS., 2005, Pages 186-196

  Jerusalem, Guy ^a,b   Hustinx, Roland ^a   Beguin, Yves ^a   Fillet, Georges ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CHU SART TILMAN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; GALLIUM 67; RITUXIMAB;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER THERAPY; CHEMOSENSITIVITY; CORRELATION ANALYSIS; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; HUMAN; IMAGING SYSTEM; INFLAMMATION; LYMPHOMA; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIOIMMUNOTHERAPY; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; TISSUE SPECIFICITY; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR BIOPSY;

EID: 23744458061     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2005.02.004     Document Type: Review

References (87)

1. D. Front, O. Israel The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients Semin Nucl Med 25 1995 60 71
2. G. Jerusalem, R. Hustinx, Y. Beguin PET scan imaging in oncology Eur J Cancer 39 2003 1525 1534
3. J.N. Rini, E.Y. Manalili, M.A. Hoffman F-18 FDG versus Ga-67 for detecting splenic involvement in Hodgkin's disease Clin Nucl Med 27 2002 572 577
4. L. Kostakoglu, J.P. Leonard, I. Kuji Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma Cancer 94 2002 879 888
5. A. Wirth, J.F. Seymour, R.J. Hicks Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma Am J Med 112 2002 262 268
6. R. Bar-Shalom, N. Yefremov, N. Haim Camera-based FDG PET and 67Ga SPECT in evaluation of lymphoma Comparative study Radiology 227 2003 353 360
7. J.W. Friedberg, A. Fischman, D. Neuberg FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma A blinded comparison Leuk Lymphoma 45 2004 85 92
8. M. Sasaki, Y. Kuwabara, H. Koga Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma Ann Nucl Med 16 2002 337 345
9. Y.Y. Shen, A. Kao, R.F. Yen Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma Oncol Rep 9 2002 321 325
10. B. Van Den Bossche, B. Lambert, F. De Winter 18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients Nucl Med Commun 23 2002 1079 1083
11. G. Jerusalem, Y. Beguin, M.F. Fassotte Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging Blood 94 1999 429 433
12. G. Jerusalem, Y. Beguin, M.F. Fassotte Early detection of relapse by whole-body positron emission tomography (PET) in the follow-up of patients with Hodgkin's disease (HD) Ann Oncol 14 2003 123 130
13. R. Elstrom, L. Guan, G. Baker Utility of FDG-PET scanning in lymphoma by WHO classification Blood 101 2003 3875 3876
14. G. Jerusalem, V. Warland, F. Najjar Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma Nucl Med Commun 20 1999 13 20
15. 18F-FDG) for the staging of low grade non-Hodgkin's lymphoma (NHL) Ann Oncol 2001 825 830
16. G. Jerusalem, Y. Beguin, M.F. Fassotte Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease Haematologica 86 2001 266 273
17. G. Jerusalem, Y. Beguin Positron emission tomography in non-Hodgkin's lymphoma (NHL) Relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL Clin Lymphoma 3 2002 56 61
18. N. Dobert, C. Menzel, N. Hamscho Atypical thoracic and supraclavicular FDG-uptake in patients with Hodgkin's and non-Hodgkin's lymphoma Q J Nucl Med Mol Imaging 48 2004 33 38
19. Jerusalem G, Hustinx R: Nuclear Medicine, in Canellos G, Lister TA, Young B (eds): The Lymphomas (ed 2). New York, Elsevier (in press)
20. J.M. Zijlstra, O.S. Hoekstra, P.G. Raijmakers 18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma Br J Haematol 123 2003 454 462
21. G. Jerusalem, V. Warland, Y. Beguin Accuracy of end of treatment 18F-FDG PET for predicting relapse in patients with Hodgkin's disease (Hd) and non-Hodgkin's lymphoma (Nhl) Proc Am Soc Clin Oncol 22 2003 572 (abstr 2299)
22. P. Mikosch, H.J. Gallowitsch, W. Zinke-Cerwenka Accuracy of whole-body 18F-FDG-PET for restaging malignant lymphoma Acta Med Austr 30 2003 41 47
23. B. Hueltenschmidt, M.L. Sautter-Bihl, O. Lang Whole body positron emission tomography in the treatment of Hodgkin disease Cancer 91 2001 302 310
24. M. Bangerter, F. Moog, M. Griesshammer Role of whole body FDG-PET imaging in predicting relapse of malignant lymphoma in patients with residual masses after treatment Radiography 5 1999 155 163
25. M.R. Weihrauch, D. Re, K. Scheidhauer Thoracic positron emission tomography using (18)F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease Blood 98 2001 2930 2934
26. C. Panizo, M. Perez-Salazar, M. Bendandi Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease mediastinal masses Leuk Lymphoma 45 2004 1829 1833
27. S. Glatz, J. Kotzerke, F. Moog Vortauschung eines mediastinalen Non-Hodgkin-Lymphomrezidivs durch diffuse Thymushyperplasie im 18F-FDG-PET Fortschr Rontgenstr 165 1996 309 310
28. M.E. Weinblatt, I. Zanzi, A. Belakhlef False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease J Nucl Med 38 1997 888 890
29. M. Sandherr, C. von Schilling, T. Link Pitfalls in imaging Hodgkin's disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose Ann Oncol 12 2001 719 722
30. M. de Wit, D. Bumann, W. Beyer Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma Ann Oncol 8 suppl 1 1997 S57 S60
31. U. Cremerius, U. Fabry, J. Neuerburg Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma Nucl Med Commun 19 1998 1055 1063
32. E. Weidmann, B. Baican, A. Hertel Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease Leuk Lymph 34 1999 545 551
33. M. de Wit, K.H. Bohuslavizki, R. Buchert 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma Ann Oncol 12 2001 29 37
34. S.N. Yoon, C.H. Park, M.K. Kim False-positive F-18 FDG gamma camera positron emission tomographic imaging resulting from inflammation of an anterior mediastinal mass in a patient with non-Hodgkin's lymphoma Clin Nucl Med 26 2001 461 462
35. P.L. Zinzani, S. Fanti, G. Battista Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients Br J Cancer 91 2004 850 854
36. H. Dittmann, M. Sokler, C. Kollmannsberger Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma Oncol Rep 8 2001 1393 1399
37. E. de Hemricourt, K. De Boeck, F. Hilte Sarcoidosis and sarcoid-like reaction following Hodgkin's disease. Report of two cases Mol Imaging Biol 5 2003 15 19
38. J.B. Bomanji, R. Syed, C. Brock Challenging cases and diagnostic dilemmas: Case 2. Pitfalls of positron emission tomography for assessing residual mediastinal mass after chemotherapy for Hodgkin's disease J Clin Oncol 20 2002 3347 3349
39. R. Naumann, B. Beuthien-Baumann, R. Fischer Simultaneous occurence of Hodgkin's lymphoma and eosinophilic granuloma - a potential pitfall in PET imaging Clin Lymphoma 3 2002 121 124
40. K.A. Cheong, N.G. Rodgers, I.D. Kirkwood Erythema nodosum associated with diffuse, large B-cell non-Hodgkin lymphoma detected by FDG PET Clin Nucl Med 28 2003 652 654
41. A. Becherer, M. Mitterbauer, U. Jaeger Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation Leukemia 16 2002 260 267
42. J. Lorenzen, M. de Wit, R. Buchert Granulation tissue pitfall in therapy control with F-18-FDG PET after chemotherapy Nuklearmedizin 38 1999 333 336
43. R. Naumann, A. Vaic, B. Beuthien-Baumann Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma Br J Haematol 115 2001 793 800
44. J.O. Armitage, D.D. Weisenburger, M. Hutchins Chemotherapy for diffuse large-cell lymphoma - rapidly responding patients have more durable remissions J Clin Oncol 4 1986 160 164
45. M. Engelhard, P. Meusers, G. Brittinger Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas Updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy Ann Oncol 2 Suppl 2 1991 177 180
46. R. Haq, C.A. Sawka, E. Franssen Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma A literature review J Clin Oncol 12 1994 1074 1084
47. A. Rahmouni, C. Tempany, R. Jones Lymphoma Monitoring tumor size and signal intensity with MR imaging Radiology 188 1993 445 451
48. D. Front, R. Bar-Shalom, M. Mor Aggressive non-Hodgkin lymphoma Early prediction of outcome with 67Ga scintigraphy Radiology 214 2000 253 257
49. M. Janicek, W. Kaplan, D. Neuberg Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy J Clin Oncol 15 1997 1631 1637
50. M. Gasparini, E. Bombardieri, M. Castellani Gallium-67 scintigraphy evaluation of therapy in non-Hodgkin's lymphoma J Nucl Med 39 1998 1586 1590
51. W.D. Kaplan, M.S. Jochelson, T.S. Herman Gallium-67 imaging A predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma J Clin Oncol 8 1990 1966 1970
52. W. Romer, A.R. Hanauske, S. Ziegler Positron emission tomography in non-Hodgkin's lymphoma Assessment of chemotherapy with fluorodeoxyglucose Blood 91 1998 4464 4471
53. N.G. Mikhaeel, A.R. Timothy, M.J. O'Doherty 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT Leuk Lymphoma 39 2000 543 553
54. G. Jerusalem, Y. Beguin, M.F. Fassotte Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma Haematologica 85 2000 613 618
55. L. Kostakoglu, M. Coleman, J.P. Leonard PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease J Nucl Med 43 2002 1018 1027
56. K. Spaepen, S. Stroobants, P. Dupont Early restaging positron emission tomography with (18)F- fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma Ann Oncol 13 2002 1356 1363
57. T. Torizuka, F. Nakamura, T. Kanno Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma Eur J Nucl Med Mol Imaging 31 2004 22 28
58. H. Young, R. Baum, U. Cremerius European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography Review and 1999 EORTC recommendations Eur J Cancer 35 1999 1773 1782
59. K. Spaepen, S. Stroobants, P. Dupont [(18)F]FDG PET monitoring of tumour response to chemotherapy Does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 30 2003 682 688
60. T. Philip, C. Guglielmi, A. Hagenbeek Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma N Engl J Med 333 1995 1540 1545
61. A.P. Anselmo, G. Meloni, E. Cavalieri Conventional salvage chemotherapy vs. high-dose therapy with autografting for recurrent or refractory Hodgkin's disease patients Ann Hematol 79 2000 79 82
62. K. Spaepen, S. Stroobants, P. Dupont Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation Blood 102 2003 53 59
63. U. Cremerius, U. Fabry, J.E. Wildberger Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma Bone Marrow Transplant 30 2002 103 111
64. B. Schot, G. van Imhoff, J. Pruim Predictive value of early 18F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma Br J Haematol 123 2003 282 287
65. J.E. Filmont, J. Czernin, C. Yap Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation Chest 124 2003 608 613
66. B. Coiffier How to interpret the radiological abnormalities that persist after treatment in non-Hodgkin's lymphoma patients? Ann Oncol 10 1999 1141 1143
67. J.A. Radford, R.A. Cowan, M. Flanagan The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease J Clin Oncol 6 1988 940 946
68. L.D. Glenn, P.P. Kumar The residual mediastinal mass following radiation therapy for Hodgkin's disease Am J Clin Oncol 14 1991 16 24
69. B. Coiffier, C. Gisselbrecht, J.M. Vose Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs J Clin Oncol 9 1991 211 219
70. M. Jochelson, P. Mauch, J. Balikian The significance of the residual mediastinal mass in treated Hodgkin's disease J Clin Oncol 3 1985 637 640
71. O. Israel, D. Front, M. Lam Gallium 67 imaging in monitoring lymphoma response to treatment Cancer 61 1988 2439 2443
72. A. Surbone, D.L. Longo, V.T. DeVita Jr Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy Significance and management J Clin Oncol 6 1988 1832 1837
73. G.P. Canellos Residual mass in lymphoma may not be residual disease J Clin Oncol 6 1988 931 933
74. G.M. Segall FDG PET imaging in patients with lymphoma A clinical perspective J Nucl Med 42 2001 609 610
75. P.L. Zinzani, M. Magagnoli, F. Chierichetti The role of positron emission tomography (PET) in the management of lymphoma patients Ann Oncol 10 1999 1181 1184
76. N.G. Mikhaeel, A.R. Timothy, S.F. Hain 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas Ann Oncol 11 2000 S147 S150
77. S.S. Foo, P.L. Mitchell, S.U. Berlangieri Positron emission tomography scanning in the assessment of patients with lymphoma Intern Med J 34 2004 388 397
78. K. Spaepen, S. Stroobants, P. Dupont Can positron emission tomography with [18F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 115 2001 272 278
79. C. Guay, M. Lepine, J. Verreault Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation J Nucl Med 44 2003 1225 1231
80. K. Spaepen, S. Stroobants, P. Dupont Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19 2001 414 419
81. N.R. Maisey, M.E. Hill, A. Webb Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? Eur J Cancer 36 2000 200 206
82. U. Cremerius, U. Fabry, J. Neuerburg Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma Nuklearmedizin 40 2001 23 30
83. W.C. Lavely, D. Delbeke, J.P. Greer FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy Int J Radiat Oncol Biol Phys 57 2003 307 315
84. O. Lang, H. Bihl, B. Hultenschmidt Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin's disease Strahlenther Onkol 177 2001 138 144
85. U. Cremerius, U. Fabry, U. Kroll Clinical value of FDG PET for therapy monitoring of malignant lymphoma - results of a retrospective study in 72 patients Nuklearmedizin 38 1999 24 30
86. T. Torizuka, K.R. Zasadny, P.V. Kison Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy Evaluation with FDG PET J Nucl Med 41 2000 999 1005
87. 18F-fluorodeoxyglucose for staging and response assessment in Hodgkin's disease, in Colombus F (ed): Progress in Hodgkin's Disease Research. Nova Science (in press)